[Drug therapy in impaired liver and kidney function].
In patients with impaired renal function the indication for a given drug, the dose and the risk of unwanted effects are altered. With simple mathematical tools, the "a priori" dose can be quantitatively adjusted to the existing renal function. However, for changes in the indications for a given drug and for checks on the effects of pharmacotherapy, only a qualitative approach is possible. In the presence of hepatic failure the same rules generally apply, though in this case no quantitative rule for reduction of the "a priori" dose can be given.
D001682:Biological Availability; D003404:Creatinine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004358:Drug Therapy; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D007674:Kidney Diseases / Q000150:complications*; D008099:Liver / Q000378:metabolism*; D008107:Liver Diseases / Q000150:complications*; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D004364:Pharmaceutical Preparations / Q000008:administration & dosage
D004364:Pharmaceutical Preparations; D003404:Creatinine
Arzneimitteltherapie bei eingeschränkter Leber- oder Nierenfunktion.